

## Association of Vitamin D Levels in Chronic Obstructive Pulmonary Disease

Vempalli Mahammad Rafi<sup>1§</sup>, Sanjay Andrew R<sup>2</sup>, Nandigam Ashok Vardhan<sup>\*3</sup>

<sup>1</sup>Research scholar, Department of physiology, Chettinad Hospital & Research Institute, Chennai.

<sup>§</sup>Tutor, Department of Physiology, Santhiram Medical College, Nandyal, Andhra Pradesh.

<sup>2</sup>Professor, Department of physiology, Chettinad Hospital & Research Institute, Chennai.

<sup>3</sup>Assistant professor, Department of Biochemistry, Government medical college, Ramagundam, Telangana.

**\*Corresponding Author:**

Nandigam Ashok Vardhan

Email ID: [ashokbiochemists@gmail.com](mailto:ashokbiochemists@gmail.com)

Cite this paper as: Vempalli Mahammad Rafi, Sanjay Andrew R, Nandigam Ashok Vardhan, (2025) Association of Vitamin D Levels in Chronic Obstructive Pulmonary Disease. *Journal of Neonatal Surgery*, 14 (19s), 218-221.

### ABSTRACT

Chronic obstructive pulmonary disease is a prevalent respiratory condition with persistent airflow limitation and significant morbidity. Emerging evidence suggests vitamin D deficiency may play a role in the disease's pathogenesis and progression. This review examines the relationship between vitamin D status and COPD, including potential mechanisms by which vitamin D may influence disease outcomes and implications for clinical management. Observational studies consistently report an association between low vitamin D levels and increased COPD risk, as well as poorer outcomes like exacerbations, hospitalizations, and mortality. Proposed mechanisms include vitamin D's anti-inflammatory, antioxidant, and immune-modulatory effects, as well as its impact on respiratory muscle function. However, randomized trials on vitamin D supplementation have shown mixed results. Further research is needed to clarify vitamin D's role in COPD, including optimal serum levels and personalized approaches. In the meantime, clinicians should consider screening for vitamin D deficiency and providing supplementation as part of comprehensive COPD management.

**Keywords** Chronic obstructive pulmonary disease, vitamin D, inflammation, exacerbations, supplementation

### 1. INTRODUCTION

Chronic obstructive pulmonary disease is a progressive respiratory condition characterized by persistent airflow limitation and respiratory symptoms, such as breathlessness, chronic cough, and sputum production (Fuggle et al., 2020). The disease is associated with various systemic manifestations, including nutritional depletion, musculoskeletal dysfunction, and metabolic disturbances (Warwick et al., 2015). These systemic effects can significantly impact the overall health and well-being of COPD patients. Recently, there has been growing interest in the potential role of vitamin D in the pathogenesis and management of COPD, as this fat-soluble vitamin is known to have important functions beyond its traditional role in calcium and bone homeostasis. Vitamin D is a fat-soluble vitamin that plays a crucial role in calcium and bone homeostasis, but it also has various extraskeletal effects, including modulating immune function and inflammatory processes.

Vitamin D deficiency appears to be more prevalent in COPD patients compared to the general population. (Dourado et al., 2006) This has prompted investigations into the potential clinical significance of vitamin D status in COPD. This review aims to examine the current evidence on the relationship between vitamin D levels and COPD, including its potential impact on disease progression, exacerbations, and associated comorbidities. (Fatima et al., 2022) (John et al., 2005) (Agustí & Soriano, 2008) (Jo, 2022).

### 2. BACKGROUND ON VITAMIN D AND COPD

Multiple studies have examined the prevalence of vitamin D deficiency among individuals with chronic obstructive pulmonary disease. A review of the literature suggests that between 30% and 80% of COPD patients may have vitamin D deficiency, depending on the population studied and the specific criteria used to define deficiency. (Cashman, 2021) Furthermore, one investigation reported that COPD patients had significantly lower serum concentrations of 25-hydroxyvitamin D compared to healthy controls, and that lower vitamin D levels were associated with more severe airflow limitations and poorer exercise capacity. (Cashman, 2021; Song et al., 2024; Yang et al., 2022)

Researchers have also explored the potential mechanisms underlying the relationship between vitamin D and COPD. Vitamin

D deficiency has been linked to increased systemic inflammation, which is a characteristic of COPD pathogenesis. (Dourado et al., 2006) Additionally, vitamin D plays a role in regulating immune function, and deficiency may contribute to the exaggerated inflammatory response observed in COPD. (Fatima et al., 2022)

The underlying reasons for the high prevalence of vitamin D deficiency in COPD are not fully understood. Proposed mechanisms include reduced sun exposure due to physical inactivity, malabsorption related to chronic inflammation, and the catabolic effects of systemic corticosteroid use. (Agustí & Soriano, 2008) Ultimately, the complex interplay between vitamin D status and COPD remains an area of active investigation.

### 3. CURRENT RESEARCH ON VITAMIN D LEVELS IN COPD

Numerous studies have examined the association between vitamin D status and various clinical outcomes in individuals with chronic obstructive pulmonary disease. Several investigations have reported that low vitamin D levels are linked to an increased risk of exacerbation, hospitalization, and mortality in this patient population. (Dourado et al., 2006) (John et al., 2005) For instance, one study demonstrated that COPD patients with vitamin D deficiency had a significantly higher risk of exacerbation and hospitalizations compared to those with sufficient vitamin D levels. (John et al., 2005) Additionally, another study found that lower serum concentrations of 25-hydroxyvitamin D were associated with more severe airflow limitation and poorer exercise capacity in COPD patients. (Dourado et al., 2006) Furthermore, some studies have suggested that vitamin D supplementation may offer potential therapeutic benefits for COPD. A systematic review and meta-analysis reported that vitamin D supplementation was associated with a reduced risk of exacerbations and improvements in lung function and exercise capacity in COPD patients. (Dourado et al., 2006) However, it is important to note that the evidence is not conclusive, and the optimal vitamin D status and therapeutic strategies in COPD remain a subject of ongoing research and debate. Further research is needed to elucidate the underlying mechanisms, determine the optimal vitamin D levels, and evaluate the long-term effects of vitamin D supplementation in COPD patients (Anchit et al., 2023; Patil et al., 2023; Song et al., 2024).

### 4. GAPS IN EXISTING LITERATURE

While the current literature has offered valuable insights into the link between vitamin D and COPD, several gaps remain that merit further investigation:

1. The underlying mechanisms connecting vitamin D deficiency to adverse clinical outcomes in COPD are not fully understood.
2. The optimal vitamin D status, as well as the appropriate dosage and duration of supplementation for COPD patients, have not been clearly established.
3. The long-term effects of vitamin D supplementation on disease progression, morbidity, and mortality in COPD patients require additional evaluation.
4. The potential interactions between vitamin D and other comorbidities commonly associated with COPD, such as cardiovascular disease and osteoporosis, necessitate more research. Addressing these gaps in the existing literature will help elucidate the role of vitamin D in the pathogenesis and management of COPD.

### 5. SIGNIFICANCE AND IMPLICATIONS

The potential clinical implications of vitamin D status in COPD are significant. Given the high prevalence of vitamin D deficiency and its association with adverse clinical outcomes, routine assessment and appropriate management of vitamin D status in COPD patients may have important therapeutic ramifications (Most et al., 2014) (John et al., 2005) (Agustí & Soriano, 2008). Improving vitamin D levels in COPD patients could potentially result in a reduction in exacerbations, hospitalization, and mortality, as well as enhancements in lung function, exercise capacity, and overall quality of life. Furthermore, addressing vitamin D deficiency may have broader implications for the management of COPD-related comorbidities, such as cardiovascular disease and osteoporosis.

The management of vitamin D status in COPD patients is crucial, as it may yield far-reaching benefits. Routine screening and targeted interventions to optimize vitamin D levels could potentially lead to a reduction in exacerbations, hospitalizations, and mortality, as well as improvements in lung function, exercise capacity, and overall quality of life for COPD patients (Most et al., 2014) (John et al., 2005) (Agustí & Soriano, 2008). Additionally, addressing vitamin D deficiency may have broader implications for the management of COPD-related comorbidities, such as cardiovascular disease and osteoporosis, which are common in this patient population.

Further research in this area could help to guide clinical practice and inform the development of more comprehensive and personalized management strategies for COPD patients. By elucidating the underlying mechanisms, optimal vitamin D

status, and long-term effects of supplementation, researchers can provide valuable insights to healthcare providers, ultimately leading to improved patient outcomes and quality of life for individuals living with COPD.

## 6. CONCLUSION

The existing literature indicates that vitamin D deficiency is common in COPD patients and may be linked to adverse health outcomes. Multiple studies have found that 30% to 80% of COPD patients have low vitamin D levels, suggesting that vitamin D status plays an important role in COPD. These studies have shown that low vitamin D is associated with increased risk of COPD exacerbations, hospitalizations, and mortality. However, more research is needed to understand the underlying mechanisms, optimal vitamin D levels, and long-term effects of vitamin D supplementation in COPD. Addressing these knowledge gaps will help clarify vitamin D's role in COPD and potentially improve patient outcomes. The high prevalence of vitamin D deficiency in COPD and its connection to poor outcomes emphasize the need for routine vitamin D assessment and management in this patient population. Improving vitamin D levels may provide benefits like reduced exacerbations, hospitalizations, and mortality, as well as better lung function, exercise capacity, and quality of life. Addressing vitamin D deficiency may also have implications for managing COPD-related conditions like cardiovascular disease and osteoporosis. Further research is crucial to guide clinical practice and develop comprehensive, personalized COPD management strategies that improve patient outcomes and quality of life.

## REFERENCES

- [1] Agustí, À., & Soriano, J. B. (2008). COPD as a Systemic Disease [Review of COPD as a Systemic Disease]. *COPD Journal of Chronic Obstructive Pulmonary Disease*, 5(2). <https://doi.org/10.1080/15412550801941349>
- [2] Anchit, Bhushan, A., & Srinivasa, B. (2023). Effect of Metformin Monotherapy and Combination Therapy with Glimepiride on Lipid Profile in Drug Naive Type-2 Diabetes Patients: A Prospective Observational Study. In *Journal of Pharmaceutical Care. Research Center for Rational Use of Drugs (RCRUD)*. <https://doi.org/10.18502/jpc.v11i1.12633>
- [3] Cashman, K. D. (2021). 100 YEARS OF VITAMIN D: Global differences in vitamin D status and dietary intake: a review of the data [Review of 100 YEARS OF VITAMIN D: Global differences in vitamin D status and dietary intake: a review of the data]. *Endocrine Connections*, 11(1). <https://doi.org/10.1530/ec-21-0282>
- [4] Dourado, V. Z., Tanni, S. É., Vale, S. A. do, Faganello, M. M., Sanchez, F. F., & Godoy, I. (2006). Manifestações sistêmicas na doença pulmonar obstrutiva crônica [Review of Manifestações sistêmicas na doença pulmonar obstrutiva crônica]. *Jornal Brasileiro de Pneumologia*, 32(2). <https://doi.org/10.1590/s1806-37132006000200012>
- [5] Fatima, M., Lamis, A., Siddiqui, S. W., Ashok, T., Patni, N., & Fadiora, O. E. (2022). Therapeutic Role of Vitamin D in Multiple Sclerosis: An Essentially Contested Concept [Review of Therapeutic Role of Vitamin D in Multiple Sclerosis: An Essentially Contested Concept]. *Cureus*. <https://doi.org/10.7759/cureus.26186>
- [6] Fuggle, N. R., Cooper, C., Oreffo, R. O. C., Price, A., Kaux, J., Maheu, E., Cutolo, M., Honvo, G., Conaghan, P. G., Bérenbaum, F., Branco, J., Brandi, M. L., Cortet, B., Veronese, N., Kurth, A., Matijević, R., Roth, R., Pelletier, J. -P., Martel-Pelletier, J., ... Reginster, J.-Y. (2020). Alternative and complementary therapies in osteoarthritis and cartilage repair [Review of Alternative and complementary therapies in osteoarthritis and cartilage repair]. *Aging Clinical and Experimental Research*, 32(4). <https://doi.org/10.1007/s40520-020-01515-1>
- [7] Jo, Y. S. (2022). Long-Term Outcome of Chronic Obstructive Pulmonary Disease: A Review [Review of Long-Term Outcome of Chronic Obstructive Pulmonary Disease: A Review]. *Tuberculosis & Respiratory Diseases*, 85(4). <https://doi.org/10.4046/trd.2022.0074>
- [8] John, M., Lange, A., Hoernig, S., Witt, C., & Anker, S. D. (2005). Prevalence of anemia in chronic obstructive pulmonary disease: Comparison to other chronic diseases. In *International Journal of Cardiology* (Vol. 111, Issue 3). <https://doi.org/10.1016/j.ijcard.2005.07.043>
- [9] Most, J. F., Possick, J. D., & Rochester, C. L. (2014). Systemic Manifestations and Comorbidities of Chronic Obstructive Pulmonary Disease. In *Clinical Pulmonary Medicine* (Vol. 21, Issue 4). <https://doi.org/10.1097/cpm.0000000000000044>
- [10] Patil, S., Nishat, S. A., & Dharapur, P. (2023). Comparing the effect of Sitagliptin versus Glimepiride on lipid profile and BMI in known case of Type 2 Diabetes Mellitus.
- [11] Song, Y., Li, J., & Wu, Y. (2024). Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders [Review of Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders]. *Signal Transduction and Targeted Therapy*, 9(1). Springer

Nature. <https://doi.org/10.1038/s41392-024-01952-8>

- [12] Warwick, E., Scourfield, A., & Quint, J. K. (2015). Systemic manifestations of chronic obstructive pulmonary disease. In British Journal of Hospital Medicine (Vol. 76, Issue 6). <https://doi.org/10.12968/hmed.2015.76.6.324>
  - [13] Yang, H., Sun, D., Wu, F., Xu, X., Liu, X., Wang, Z., & Zhou, L. (2022). Effects of Vitamin D on Respiratory Function and Immune Status for Patients with Chronic Obstructive Pulmonary Disease (COPD): A Systematic Review and Meta-Analysis. Computational and Mathematical Methods in Medicine, 2022, 1. Hindawi Publishing Corporation. <https://doi.org/10.1155/2022/2910782>
-